Related Experiment Video
Updated: Jan 9, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Diversifying the triquinazine scaffold of a Janus kinase inhibitor
Kleni Mulliri1, Kris Meier1, Johanna-Dorothea Feuchter1
1Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern Freiestrasse 3 Bern CH-3012 Switzerland jean-louis.reymond@unibe.ch.
Abstract:
The exploration of novel three-dimensional scaffolds remains essential for expanding chemical space and discovering new bioactive molecules. Here, we describe a robust synthetic strategy that enables modulation of Janus Kinase activity through systematic diversification of the triquinazine skeleton, a highly sp3-rich scaffold derived from generated databases (GDBs). By employing ring enlargement and deconstruction approaches, four unprecedented chiral scaffolds were accessed, leading to the synthesis of 26 analogues. Biological evaluation against the Janus kinase family demonstrated how subtle modifications to the triquinazine skeleton influence the activity against JAK1, JAK2, JAK3, and TYK2. Notably, compound (S,R,R)-40a emerged as a potent JAK1 inhibitor (IC50 = 18 nM), with similar potency as the FDA-approved inhibitors abrocitinib and upadacitinib. These findings highlight the potential of GDB-inspired molecules as a source for drug discovery.
More Related Videos
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Related Concept Videos
The JAK-STAT Signaling Pathway
Dipeptidyl Peptidase 4 Inhibitors
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
cAMP-dependent Protein Kinase Pathways